© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Daunorubicin Hydrochloride came out of an age when researchers sought more than band-aid remedies for cancer. In the 1960s, two independent labs discovered the compound from a strain of soil bacteria. As a working chemist, I’ve seen how discoveries often come from chance encounters and hard grind in basic research. Early adopters in Italy and France recognized its power against leukemia cells, which turned out to be a shot of hope for patients and their doctors. Over time, as safety data and clinical results piled up, the drug moved out of labs and into hospitals as a mainstay for treating specific leukemias.
Today, Daunorubicin Hydrochloride stands as an anthracycline antibiotic, with a primary role in treating acute myeloid and lymphoblastic leukemia. It doesn’t fall into the household-name category, yet doctors who fight blood cancers know it well. You won’t find it in a family medicine cabinet since this drug demands careful dosing and skilled hands for administration. For many, its reputation rides on its ability to intercalate DNA, stop cell division, and trigger cell death in cancer cells.
This compound shows up as a red to orange powder, pulling moisture from the air if left open. Its molecular weight sits at 564.98 g/mol, with a melting point above 200°C — no surprise for a molecule built to withstand hostile environments in the body. Water solubility matters for doctors preparing IV solutions. Its hydrochloride form gives the compound a handle for formulation since that salt is more stable than the free base. You can spot it by its deep color, which comes from its quinone structure, and its tendency to decompose in strong light or extreme pH, calling for careful storage.
Vials usually contain a specified dose, anywhere from 20 to 100 mg, with labels making it clear this is a hospital-use drug. Labels mention its storage at 2-8°C, keeping out of light, and the need to reconstitute just before use. Instructions flag its vesicant risk, warning against extravasation. From my own work with these types of agents, labeling becomes not only a legal shield but a practical guide for avoiding errors that carry life-altering consequences. Manufacturing lots must track purity, residual solvents, and microbial limits, since the smallest contamination can spell disaster for compromised patients.
Fermentation comes first, using cultures of Streptomyces peucetius. Growth conditions, nutrients, and time all need constant monitoring. After harvesting, the broth goes through extraction steps–usually solvent separation, followed by purification on chromatography columns. The final molecule takes shape through conversion to the hydrochloride salt, filtering, and vacuum-drying. I’ve spent days optimizing similar processes—every tweak in pH, temperature, or time can change yield and safety. Poor cGMP practices won’t fly here, given regulatory scrutiny.
Daunorubicin’s structure begs for chemists to tinker. By modifying sugar groups or swapping out functional groups on the anthracycline ring, scientists have chased reductions in toxicity and boosts in efficacy. Early offshoots produced doxorubicin, which broadens the cancer-type reach. Enzyme-linked conjugates, pegylation, and nanoparticle encapsulation aim to change how the drug lands in tumor tissue versus healthy marrow. Chemical modifications also serve in making analogs with altered pharmacokinetics, getting more medicine into cancer cells and less into vulnerable heart tissue. It’s a game of trade-offs for anyone designing the next-generation improvements.
The molecule’s naming history traces changing hopes and different developers. “Daunomycin” was one of the first handles; it also carries trade names like Cerubidine and Rubidomycin. Hospital pharmacies often know it simply as “dauno,” which helps avoid confusion with similarly named cousins. The chemical registers under CAS number 23541-50-6 and sometimes lands on shelves as daunorubicin HCl for clarity.
No one goes in blind with a vial of daunorubicin. Handling standards require glove use, eye shields, and negative-pressure hoods. Even small spills or aerosolized particles create exposure risks, so protocols call for special spill kits and detailed logs of waste handling. Nurses infuse it through secure IV lines, double-checking dose, and watching patients for allergic reactions or signs of extravasation. For hospitals, compliance goes beyond following checklists. Institutional policies rely on drug audits, staff education, and regular training updates. Safe operation depends on vigilance, and from what I’ve seen on clinical teams, experienced eyes spot trouble before it turns serious.
Pediatric and adult oncology teams see daunorubicin in treatment protocols for acute leukemias, often combined with cytarabine and other chemotherapy agents. Protocol design comes from heaps of clinical trial data, refining doses to strike at leukemic cells while preserving enough bone marrow function for recovery. Sometimes, this drug appears outside cancer care in research settings—its DNA-binding action lets scientists probe basic cell biology. Its use as first-line therapy has persisted for decades, testifying to its reliable action when facing aggressive hematologic malignancies. Clinical experience tells a different story than bench data; patients and families weigh short-term side effects against the hope for long-term remission.
Drug developers keep circling back to daunorubicin, searching for ways to sidestep its characteristic cardiac toxicity. Nanoparticles, slow-release formulations, and prodrugs have moved from animal tests to early human trials. Some research labs push for more personalized regimens, using genetic tests to predict who metabolizes the drug quickly or who stands at risk of severe side effects. New synergies—combining daunorubicin with immunotherapies or targeted antibodies—have brought modest improvements so far. It takes years to move new ideas from pipettes to patient wards, but the work continues since leukemia survival rates still fall short for too many patients.
The big cloud hanging over daunorubicin remains its effect on the heart. Decades of animal and clinical studies have mapped out dose thresholds and warning signs. Physicians monitor heart function with regular echocardiograms, and toxicity research keeps pressing for earlier predictors of risk. No dose of daunorubicin escapes side effects; even standard regimens cause hair loss, mouth sores, and periods of immune suppression that open doors to infection. Long-term survivors face a ticking clock on possible delayed-onset cardiac problems. Researchers and clinicians stay on this trail, refining supportive measures and dosing strategies to keep the balance tilting toward benefit.
Machines capable of spotting early toxicity, plus regimens crafted for a patient’s exact genetics, offer hope for the next generation. Modern research culture calls for more open data sharing, and that pushes new ideas into journals and, eventually, into standard practice—faster. Scientists dig deeper into structure-activity relationships to invent new analogs that slip past drug pumps or sneak into resistant cells. Global health programs aim to boost access to conventional chemotherapy drugs like daunorubicin, especially in low- and middle-income countries where the leukemia burden is rising. The work won’t quit. For now, every advance in formulation, dosing, or delivery gives one more leukemia patient a shot at years ahead, not just months.
Cancer treatment comes with tough decisions. Some options push back the disease, others slow it down, and a select few hold promise for long-term control. Among these, daunorubicin hydrochloride stands out. This medicine has proven itself valuable for people with acute leukemia, including both adults and children. As a chemotherapy drug, daunorubicin has developed a track record that stretches back over fifty years, giving doctors a reliable weapon in the fight against certain blood cancers. From personal observation in hospital settings, daunorubicin remains one of the main choices oncologists rely on. There’s a good reason for this—leukemia hits fast and hard, and treatment decisions can’t wait.
Chemotherapy attempts to destroy cancer cells as quickly as they multiply. Daunorubicin hydrochloride belongs to a group of medicines called anthracyclines. These drugs dig right into the DNA of cancer cells. By binding directly to the genetic material, daunorubicin slows—or even stops—the process that allows cancer to copy itself and spread through the body. Anyone who’s watched a loved one cope with leukemia knows the damage it can do when left unchecked, so a drug that attacks cancer at its core matters. Even though side effects like hair loss, fatigue, or infection risk often appear, patients and their families frequently say they feel hope because of this therapy's impact.
Patients battling acute lymphoblastic leukemia or acute myeloid leukemia often face grim odds without fast intervention. Daunorubicin offers something concrete—a fighting chance. I have seen parents find hope when their child’s blood counts finally start moving in the right direction after rounds of this medicine. Survivors sometimes return years later and credit their progress to the course of treatment that started with daunorubicin. That sense of hope gives medical teams and families courage to continue through rough patches.
Daunorubicin isn’t perfect. It can cause damage to the heart if used for too long or in high doses. Doctors need to balance effectiveness with safety, running regular tests so damage can be caught early. In some cases, the medication may lead to complications that slow or even stop treatment. Patients often need extra support—cardiology input, extra medications, or changes to the treatment protocol. These realities highlight the need for close follow-up by skilled oncology teams. There’s always room for better cancer medicines, fewer side effects, and more tailored care. Recent studies show careful dosing schedules reduce risks, but vigilance remains key.
Some hospitals now use genetic testing to predict which patients will respond best to daunorubicin. Others try new methods like combining the drug with immunotherapies or targeted agents to improve results. Research into heart-protective drugs continues, aiming to safeguard patients who might need long courses. Families facing leukemia deserve updated, safe options and honest information about benefits and challenges. Through innovation and dedication, caregivers and scientists keep working toward that goal.
Daunorubicin hydrochloride often serves as a cornerstone in treating certain cancers, especially leukemia. The stories from clinics and families point to real change brought about by this medicine. With a combination of practical experience, scientific evidence, and relentless searching for better answers, medical teams keep hope alive for those in some of life’s toughest battles.
Daunorubicin hydrochloride saves many lives as part of chemotherapy regimens. Anyone getting ready to start treatment wants clear, honest talk about what this medicine can do—and what it can do to them. For families, hard information means less anxiety and fewer surprises.
Nausea comes up often when people tell their stories about taking daunorubicin. Kids and adults alike face queasy stomachs, sometimes with vomiting. Doctors commonly prescribe anti-nausea pills before infusions. Even with those, I’ve seen patients prefer bland foods or stick to small meals to manage sick feelings. Constipation or diarrhea pop up, too, so patients need to watch for changes.
Hair loss hits many, and it feels personal. Patients can feel unrecognizable looking in the mirror. Some folks shave their heads early, others wait it out. On the plus side, hair growing back usually comes with celebration and fresh hope after treatment ends.
Fatigue weighs heavier than anyone expects. This isn’t needing a nap—fatigue from daunorubicin knocks the wind out of ordinary activities like walking the dog or picking up groceries. Young and old often wind up needing more help at home. Planning for extra rest, lowering expectations, and keeping open conversations within the family reduce frustration.
The medicine targets fast-growing cells. Cancer fits that bill, but so does bone marrow churning out blood cells. Many patients see drops in white cells, red cells, or platelets. Low white counts mean higher risk of infections, even from little scratches or crowded places. Some stay away from school, big gatherings, or playgrounds during certain weeks.
Anemia from low red cells shows up as shortness of breath or feeling lightheaded even without exercise. Transfusions sometimes help people through rough patches. Low platelets might bring easy bruising or nosebleeds. Patients keep an eye out for small bleeds, and caregivers check their gums and skin.
Daunorubicin can stress the heart, especially in higher doses or with other heart-toxic drugs. This risk makes regular heart checks part of treatment, even for the young. I’ve heard of cases where stopping or lowering doses keeps a patient’s heart safe. Cardiologists often step in to counsel patients with high blood pressure or family risk for heart trouble.
Good hydration and gentle exercise make small, steady differences in managing chemo’s punch. Nurses play a huge role, checking numbers and reminding families of warning signs. Anyone on daunorubicin should keep up with checkups, share new symptoms, and never feel embarrassed to ask about little changes in their health or habits. Support groups—whether in person or online—help by sharing tips that aren’t in the handbook.
Doctors work with pharmacists to customize anti-nausea regimens and prevent more dramatic dips in blood counts. Some centers offer clinics specifically for managing treatment side effects, which helps steer away from emergency hospital visits. Staying proactive and honest—between patients, families, and the care team—creates room for better days, even in the toughest rounds of chemo.
Every experience has its ups and downs, but knowing the landscape ahead makes the journey with daunorubicin less frightening and more manageable.
Dealing with cancer goes far beyond the diagnosis. There’s fear, fatigue, and an ever-growing stack of information about different treatments. Daunorubicin hydrochloride turns up as one of the main drugs in treating certain kinds of leukemia. Most people won’t ever need to remember its name, but for those who do, every step matters. I’ve seen loved ones go through chemotherapy, and one thing becomes clear fast—a simple question like “How does this drug get into my body?” gets packed with urgency and anxiety.
Daunorubicin hydrochloride takes a direct route: it goes straight into a vein through intravenous (IV) injection or infusion. No pills to swallow, no patch to stick on. Nurses mix the drug, double-check doses, and get everything ready with strict protocols in place. Every detail counts, down to the colors of the tubing, gloves, and disposal bags, because this drug carries serious power. Giving it through a vein allows it to move quickly through the bloodstream and reach cancer cells—wherever they try to hide.
The idea of an IV isn’t new for anyone who’s spent time in hospitals. What sets daunorubicin hydrochloride apart is its bright red color—nurses sometimes call it "the red devil"—and its reputation for being tough on both the cancer and the body. The infusion can take about 30 minutes and happens in cycles, often in combination with other chemotherapy agents. Precise scheduling helps doctors attack more cancer cells while giving healthy cells a chance to recover between cycles.
The delivery route shapes how medicines work. Taking a pill might seem easier, but some chemotherapy drugs wouldn’t survive the stomach or liver. Direct IV infusion keeps daunorubicin active and lets doctors deliver exact doses. That accuracy matters—too little, and the drug falls short; too much, and the risk of side effects jumps. Side effects remain a real challenge. Daunorubicin can cause hair loss, mouth sores, and especially impact the heart. This places extra demands on both patients and the care team to track health closely and adjust as needed.
Hospitals and clinics use strict training and resources to keep this precise delivery as safe as possible. Patients count on their team to spot problems quickly, like pain at the injection site that could mean leakage—a risk with IV chemotherapy. Medical staff monitor patients for reactions, check blood counts, and measure heart function before moving to the next cycle.
There’s a lot riding on clear communication. Nurses and pharmacists explain everything, from what the infusion feels like to tips for managing nausea at home. I’ve watched people push through side effects because they believe the fight is worth it. Support services—social workers, nutrition advice, counseling—often make the journey more manageable. Patients need those resources and deserve the chance to ask questions without judgment.
Medicine keeps evolving. Researchers explore new delivery techniques, try gentler dosing schedules, and look for ways to protect the heart. Some hospitals offer vein-sparing devices for people whose veins take a beating during repeated chemotherapy. There’s hope in the science pushing forward and in the simple determination of patients and caregivers.
For those facing treatment with daunorubicin hydrochloride, there’s reassurance knowing that even a powerful, intimidating drug like this gets handled with care, skill, and a lot of heart from the people delivering it. That care can make an impossible situation feel a bit more bearable.
Daunorubicin Hydrochloride treats serious blood cancers like leukemia. Caregivers and patients both need to respect the power this drug carries. My experience working with chemotherapy patients gets me straight to the truth: this drug can save lives, but it can turn on the patient just as quickly if mishandled.
Nobody should handle Daunorubicin without proper protective gear. Gloves, gowns, and eye protection all play a role. Splashing or touching the solution can hurt healthy skin, causing painful ulcers. Once, I met a nurse with a scar on her forearm from a single careless day in the chemo clinic. Always check for damage or leaks before opening the vial.
Doctors give Daunorubicin intravenously, slowly. Rushing leads to burning, swelling, or tissue damage if it leaks into the skin. If you feel pain or stinging around the injection site, don’t stay silent—alert the nurse. This drug should never go in the muscle or under the skin, and never by mouth.
This drug brings the risk of infection. I remember patients who felt fine one day, but got a fever the next, then landed in the hospital with life-threatening infections. The reason? Daunorubicin wipes out white blood cells, leaving the door wide open for germs. Frequent blood tests track these cell counts. Patients need to wash hands often and avoid crowds. Any fever or chills, no matter how minor, deserve immediate attention.
Heart problems matter just as much. Daunorubicin can weaken the heart muscle over time. The risk climbs with each dose. Before starting, patients undergo heart checks. I’ve watched cardiologists pore over those scans, looking for even the smallest changes. Breathing trouble, swelling in the feet, or sudden weight gain can signal heart failure. Ignoring these warning signs can put treatment, and your life, in danger.
Healthy habits tip the odds in your favor. Staying hydrated helps the kidneys flush out the drug and lessens kidney stress. It also prevents some of the severe mouth sores that trouble patients. Nutritious food helps the body repair itself. I’ve seen folks try to tough out mouth pain or nausea, but reporting issues early gets you faster relief.
People taking this medicine need full honesty from their medical team about what other drugs or supplements they use. Some antibiotics, antifungals, and other chemo drugs play badly with Daunorubicin. Even herbal teas can cause surprises. My patients often forget to mention those, thinking “natural” means “safe.” It doesn’t.
Caregivers sometimes let their guard down cleaning up body fluids. Daunorubicin stays active in urine, stool, or vomit for days. Spills or splatters should be cleaned up with gloves, bleach, and disposable towels. Never wash contaminated clothing with the rest of the laundry.
Every round of chemo brings new risks. Weekly doctor visits might feel repetitive, but one missed sign can change everything. The best defense comes from honest updates between patient and doctor, blood tests, and a readiness to act on problems fast.
Daunorubicin Hydrochloride can be tough medicine. Paying close attention—by the patient, family, and care team—makes the most difference. It’s a matter of survival, not just treatment.
Chemotherapy throws life into sharp focus. Many who hear about daunorubicin hydrochloride know it as a powerhouse against certain cancers. What doesn’t get enough attention is how easily one medicine can complicate another. Medications don’t just work alone. They move and wrestle with each other inside the body in ways that can change everything, for better or worse.
Drug interactions aren’t minor details. Since daunorubicin affects both the heart and immune cells, the list of possible clashes isn’t short. Antibiotics, antifungals, and some heart medicines share the same highways in the bloodstream as daunorubicin. In practice, this leads to more intense side effects. For example, I watched a family friend fighting leukemia struggle with unexpected fatigue and infections. One cause traced to a new medicine prescribed for a slight cough. The two drugs fought for dominance, and her body paid the price.
Older chemotherapy drugs like daunorubicin often get paired with steroids or other anti-cancer agents. Combinations like these can put huge stress on the liver and kidneys, which play defense, clearing everything out. If doctors add medicines for nausea or antibiotics to fight fevers, the filter organs can get overwhelmed fast.
Certain medicines known as CYP3A4 inhibitors or inducers, including some for fungal infections (like ketoconazole) and seizure control (like phenytoin), can shift daunorubicin’s levels up or down. Raising daunorubicin levels brings the risk of more severe side effects. Too much fatigue, lowering of blood counts, and heart muscle problems happen more often in people whose bodies can’t clear the drug efficiently. Medications lowering the immune response, like cyclosporine, often magnify this danger.
Blood thinners, including warfarin, throw another challenge into the mix. Both daunorubicin and these drugs affect blood cells and clotting, so the chance of bleeding climbs if someone uses both without careful monitoring. Even something as routine as an over-the-counter painkiller or an herbal supplement can change how daunorubicin is absorbed or processed.
Nobody should navigate this alone. Bringing every single medication—prescription and otherwise—into conversation with the oncology team helps a lot. Electronic health records help by flagging risky combinations, but not every dangerous interaction gets caught. Having a written log and keeping all providers in the loop can mean the difference between a smooth round of treatment and an emergency trip to the hospital.
I’ve seen firsthand how cancer patients sometimes skip mentioning vitamins, antacids, or even tea blends. These seem harmless, yet plant extracts or minerals sometimes block or delay medicine absorption. Keeping a habit of asking the pharmacist every time something new is suggested or picking up the phone before taking non-prescribed treatments saves a lot of trouble.
Doctors base decisions on lab results, but a patient’s sense of well-being and history with side effects matter just as much. Getting frequent blood tests and regular check-ins let the team spot liver, heart, or immune problems before they snowball. If a new drug is truly necessary, tweaking dosages of daunorubicin or picking a safer alternative helps lower risks. Education goes a long way—patients who understand why each medicine is chosen usually watch for and report problems sooner.
Interacting drugs turn a tough road even tougher, but steady communication and routine monitoring can turn down the risk. Cancer care beats the odds most often when everyone talks honestly, questions choices, and shares every detail that matters.
| Names | |
| Preferred IUPAC name | (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione hydrochloride |
| Other names |
Cerubidine Daunomycin hydrochloride Rubidomycin hydrochloride |
| Pronunciation | /ˌdɔː.nɔː.rʊˈbɪ.sɪn haɪˌdrɒk.ləˈraɪd/ |
| Identifiers | |
| CAS Number | '23541-50-6' |
| 3D model (JSmol) | `3D model (JSmol)` string for **Daunorubicin Hydrochloride**: ``` CC1=C(C(=O)C2=C(C1=O)C3C(C(C(C(O3)CO)O)O)O)C4=CC=CC=C4N5C=CC=CC5=O.Cl ``` |
| Beilstein Reference | 1364708 |
| ChEBI | CHEBI:44935 |
| ChEMBL | CHEMBL178 |
| ChemSpider | 2174 |
| DrugBank | DB00694 |
| ECHA InfoCard | 13a3d151-377d-4e85-bd9c-0e0325dcb59c |
| EC Number | EC 3.1.4.17 |
| Gmelin Reference | 84554 |
| KEGG | D03899 |
| MeSH | D003638 |
| PubChem CID | 30323 |
| RTECS number | HE5950000 |
| UNII | 85289873R1 |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID4028295 |
| Properties | |
| Chemical formula | C27H29NO10·HCl |
| Molar mass | 564.98 g/mol |
| Appearance | A red, lyophilized powder. |
| Odor | Odorless |
| Density | 1.48 g/cm3 |
| Solubility in water | Soluble in water |
| log P | 0.85 |
| Acidity (pKa) | pKa = 7.48 |
| Basicity (pKb) | 5.89 |
| Magnetic susceptibility (χ) | -10,700·10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.668 |
| Viscosity | Viscous liquid |
| Dipole moment | 7.61 D |
| Pharmacology | |
| ATC code | L01DB02 |
| Hazards | |
| Main hazards | May cause cancer. Causes damage to organs. Causes serious eye irritation. Causes skin irritation. May cause genetic defects. |
| GHS labelling | GHS05, GHS06, GHS08 |
| Pictograms | GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H301 + H331: Toxic if swallowed or if inhaled. H317: May cause an allergic skin reaction. H350: May cause cancer. H373: May cause damage to organs through prolonged or repeated exposure. |
| Precautionary statements | P201, P202, P264, P270, P280, P308+P313, P405, P501 |
| NFPA 704 (fire diamond) | NFPA 704: 3-3-2 |
| Flash point | Flash point: 233.3°C |
| Lethal dose or concentration | LD50 = 21 mg/kg (IV in mouse) |
| LD50 (median dose) | LD50 (median dose) Daunorubicin Hydrochloride: 2.38 mg/kg (Intravenous, Mouse) |
| NIOSH | Not Listed |
| PEL (Permissible) | 0.1 mg/m³ |
| REL (Recommended) | 50‒60 mg/m² daily for 3 days |
| IDLH (Immediate danger) | IDLH: Not Listed |
| Related compounds | |
| Related compounds |
Daunorubicin Doxorubicin Idarubicin Epirubicin Mitoxantrone |
